Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octaplex in Acute Major Bleeding on DOAC Therapy
NCT04867837Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Sep 2021
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of balfaxar in Acute major hemorrhage, sponsored by Octapharma. Started Sep 2021; status: terminated.
02
Drugs
balfaxar
03
Conditions
Acute major hemorrhage
Beyond the preview
Go deeper on NCT04867837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867837.